Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
Sponsor: Oyster Point Pharma, Inc.
Listed as NCT03633461, this PHASE2 trial focuses on Dry Eye Disease and remains completed. Sponsored by Oyster Point Pharma, Inc., it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Nov 2018 — Sep 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oyster Point Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .